FORM 10-Q


                       Securities and Exchange Commission
                             Washington, D. C. 20549

         (Mark One)
              X            Quarterly Report Pursuant to
                           Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                      For Quarter Ended: February 28, 1999
                                       OR
               _ Transition Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                         Commission File Number: 0-14820

                                  IMMUCOR, INC.
             (Exact name of registrant as specified in its charter)


                       Georgia                           22-2408354
             (State or other jurisdiction of          (I.R.S. Employer
             incorporation or organization)           Identification No.)

          3130 Gateway Drive P.O. Box 5625 Norcross,Georgia    30091-5625
          (Address of principal   executive   offices)         (Zip Code)

                  Registrant's telephone number: (770) 441-2051

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                  Yes X    No

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

         As of April 10, 1999: Common Stock, $. 10 Par Value - 7,438,405


<PAGE>

                                 IMMUCOR, INC.
                      Condensed Consolidated Balance Sheets

                                     February 28                    May 31,
ASSETS                                  1999                          1998
                                     (Unaudited)                   (Audited)
                                   ----------------              ---------------
Current assets:
  Cash and cash equivalents             $1,720,774                  $15,816,217
  Accounts receivable, net              19,561,186                   12,214,270
  Accounts receivable, other               168,963                      695,430
  Inventories                           14,103,333                    8,462,850
  Income taxes receivable                  126,544                       95,166
  Deferred income taxes                    380,123                      370,029
  Other assets                           1,012,016                      447,661
                                   ----------------              ---------------
    Total current assets                37,072,939                   38,101,623

Long-term investment                     1,000,000                    1,000,000

Property and equipment, at cost         19,992,891                   10,505,766
  less accumulated depreciation         (5,351,086)                  (4,486,974)
                                   ----------------              ---------------
                                        14,641,805                    6,018,792

Other assets, net                        2,982,341                      801,779

Cash value of life insurance             1,580,664                            0

Excess of cost over net tangible
  assets acquired, net                  27,851,389                   11,622,082
                                   ----------------              ---------------

                                       $85,129,138                  $57,544,276
                                   ================              ===============

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Current portion of long-term 
       obligations                        $534,036                     $359,325
  Accounts payable                       5,661,877                    3,069,973
  Income taxes payable                     302,699                      359,598
  Accrued salaries and wages               724,631                      862,550
  Other accrued liabilities              1,564,475                      501,739
                                   ----------------              ---------------
    Total current liabilities            8,787,718                    5,153,185

Long-term obligations                   33,444,459                    8,911,727

Deferred income taxes                    1,403,458                    1,046,814

Other liabilities                        2,917,738                            0

Shareholders' equity:
  Common stock, $.10 par value             743,691                      807,881
  Additional paid-in capital            16,120,647                   22,079,468
  Retained earnings                     24,257,873                   21,937,697
  Accumulated other comprehensive loss  (2,546,446)                  (2,392,496)
                                    ----------------             ---------------

    Total shareholders' equity          38,575,765                   42,432,550
                                    ----------------             ---------------

                                       $85,129,138                  $57,544,276
                                    ================             ===============

See accompanying notes.

<PAGE>

                                  IMMUCOR, INC.
                   Condensed Consolidated Statements of Income
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                Three Months Ended                        Nine Months Ended
                                          February 28,        February 28,        February 28,        February 28,
                                              1999                1998                1999                1998
                                         ----------------    ---------------     ----------------    ----------------
<S>                                             <C>                 <C>                  <C>                <C>

Net sales                                    $16,758,106        $10,155,231          $40,782,061         $29,620,819
Cost of sales                                  7,589,998          4,792,144           18,558,724          13,401,159
                                         ----------------    ---------------     ----------------    ----------------
Gross profit                                   9,168,108          5,363,087           22,223,337          16,219,660

Research and development                         413,335            259,188            1,000,707             728,566
Selling and marketing                          3,045,981          1,789,660            7,337,310           5,317,683
Distribution                                     964,498            571,134            2,262,647           1,738,740
General and administrative                     2,339,135          1,683,030            6,132,643           5,097,192
Merger-related expenses                          120,331                  0              432,692                   0
Amortization expense                             329,543            144,168              710,777             446,687
                                         ----------------    ---------------     ----------------    ----------------
Total operating expenses                       7,212,823          4,447,180           17,876,776          13,328,868
                                         ----------------    ---------------     ----------------    ----------------

Income from operations                         1,955,285            915,907            4,346,561           2,890,792

Interest income                                   19,697            189,763              305,630             588,259
Interest expense                                (516,843)          (155,794)            (903,322)           (474,895)
Other income (expense)                            18,268            (94,630)              93,695            (104,602)
                                         ----------------    ---------------     ----------------    ----------------
Total other                                     (478,878)           (60,661)            (503,997)              8,762
                                         ----------------    ---------------     ----------------    ----------------

Income before income taxes                     1,476,407            855,246            3,842,564           2,899,554

Income taxes                                     500,310            390,023            1,522,388           1,330,269
                                         ----------------    ---------------     ----------------    ----------------

Net income                                      $976,097           $465,223           $2,320,176          $1,569,285
                                         ================    ===============     ================    ================

Earnings per share:

     Basic                                         $0.13              $0.06                $0.30               $0.19
                                         ================    ===============     ================    ================

     Diluted                                       $0.13              $0.06                $0.29               $0.19
                                         ================    ===============     ================    ================


Weighted average shares outstanding:

     Basic                                     7,459,589          8,090,594            7,711,459           8,089,905
                                         ================    ===============     ================    ================

     Diluted                                   7,720,680          8,408,038            7,981,352           8,459,165
                                         ================    ===============     ================    ================

</TABLE>


See accompanying notes.

<PAGE>
                                    IMMUCOR, INC.
                  Condensed Consolidated Statements of Cash Flows
                                    (Unaudited)
<TABLE>
<CAPTION>

                                                           Nine Months Ended
                                                     February 28,       February 28,
                                                         1999               1998
                                                     -------------      -------------
<S>                                                       <C>                <C>

OPERATING ACTIVITIES:
  Net income                                           $2,320,176         $1,569,285
  Adjustments to reconcile net income to
    net cash provided by operating activities:
      Depreciation                                      1,219,312          1,017,668
      Amortization                                        710,777            443,364
      Changes in assets and liabilities:
        Accounts receivable                            (3,755,190)        (1,085,086)
        Accounts receivable, other                        526,467             95,362
        Income tax receivable                             233,246             (1,946)
        Inventories                                    (1,955,139)          (190,668)
        Other current assets                              245,457           (204,369)
        Accounts payable                                1,294,808           (956,678)
        Income taxes payable                              (89,989)            64,207
        Other current liabilities                         385,006            267,841
                                                     -------------      -------------

Cash provided by operating activities                   1,134,930          1,018,980

INVESTING ACTIVITIES:
  Purchase of / deposits on property and equipment     (2,344,313)          (974,703)
  Cash paid for acquisition, net of cash acquired     (25,658,125)                 0
  Acquisition-related severance                        (1,957,940)                 0
  Increase / decrease in other assets                  (3,222,946)            34,822
                                                     -------------      -------------

Cash used in investing activities                     (33,183,324)          (939,881)

FINANCING ACTIVITIES:
  Borrowings under line of credit agreements           25,200,000                  0
  Repayment of notes payable / line of credit          (1,299,200)          (842,427)
  Exercise of stock options and warrants                1,330,996            328,911
  Purchase and retirement of stock                     (7,354,007)          (151,615)
                                                     -------------      -------------

Cash provided by (used in) financing activities        17,877,789           (665,131)

EFFECT OF EXCHANGE RATE CHANGES ON CASH                    75,163           (552,627)
                                                     -------------      -------------

DECREASE IN CASH
  AND CASH EQUIVALENTS                                (14,095,443)        (1,138,659)

CASH AND CASH EQUIVALENTS
  AT BEGINNING OF PERIOD                               15,816,217         15,718,234
                                                     -------------      -------------

CASH AND CASH EQUIVALENTS
 AT END OF PERIOD                                      $1,720,774        $14,579,575
                                                     =============      =============

Noncash investing and financing activities:
  Fair value of assets acquired                       $17,757,750
  Cost in excess of assets acquired                    17,078,722
  Liabilities assumed                                  (9,178,347)
                                                     =============
  Net cash paid for acquisition                       $25,658,125
                                                     =============
</TABLE>


See accompanying notes.
<PAGE>

                                  IMMUCOR, INC.
              Notes to Condensed Consolidated Financial Statements
                                   (Unaudited)


1.     BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information  and the  instructions  to Form  10-Q and  Article  10 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial  statements.  However,  there  has  been  no  material  change  in the
information disclosed in the Company's annual financial statements dated May 31,
1998, except as disclosed herein. In the opinion of management,  all adjustments
(consisting  of  normal  recurring  accruals)  considered  necessary  for a fair
presentation  have been  included.  Operating  results for the nine month period
ended February 28, 1999 are not  necessarily  indicative of the results that may
be expected for the year ending May 31, 1999. For further information,  refer to
the  consolidated  financial  statements and footnotes  thereto  included in the
Company's Annual Report on Form 10-K for the year ended May 31, 1998.

2.       INVENTORIES
Inventories are stated at the lower of first-in, first-out cost or market:

                                        As of                      As of
                                  February 28, 1999            May 31, 1998
                                 --------------------      -------------------
Raw materials and supplies              $3,217,761                  $2,668,444
Work in process                            901,738                     762,475
Finished goods                           9,983,834                   5,031,931
                                 ====================      ===================
                                       $14,103,333                  $8,462,850
                                 ====================      ===================

3.     EARNINGS PER SHARE
In 1997, the Financial  Accounting  Standards Board ("FASB") issued Statement of
Financial  Accounting  Standards No. 128, Earnings per Share ("Statement  128").
Statement 128 replaced the calculation of primary and fully diluted earnings per
share with basic and diluted  earnings per share.  Unlike  primary  earnings per
share,  basic  earnings  per share  excludes  any  dilutive  effects of options,
warrants and convertible securities.  Diluted earnings per share is very similar
to the previously  reported fully diluted  earnings per share.  All earnings per
share  amounts  for all  periods  have been  presented,  and where  appropriate,
restated to conform to the Statement 128 requirements.  The following table sets
forth the computation of basic and diluted earnings per share.

<TABLE>
<CAPTION>

                                                         Three Months Ended                Nine Months Ended
                                                    February 28,     February 28,     February 28,     February 28,
                                                        1999             1998             1999             1998
                                                   ---------------- ---------------  ---------------- ---------------
<S>                                                          <C>           <C>                <C>            <C>

Numerator for basic and diluted earnings per share:
  Income available to common shareholders                 $976,097        $465,223        $2,320,176      $1,569,285
                                                   ================ ===============  ================ ===============

Denominator:
  For basic earnings per share - weighted
  average basis                                          7,459,589       8,090,594         7,711,459       8,089,905

  Effect of dilutive stock options and warrants            261,091         317,444           269,893         369,260
                                                   ---------------- ---------------  ---------------- ---------------
                                                   
  Denominator for diluted earnings per share -
  adjusted weighted-average shares                       7,720,680       8,408,038         7,981,352       8,459,165
                                                   ================ ===============  ================ ===============

Basic earnings per share                                     $0.13           $0.06             $0.30           $0.19
                                                   ================ ===============  ================ ===============

Diluted earnings per share                                   $0.13           $0.06             $0.29           $0.19
                                                   ================ ===============  ================ ===============

</TABLE>
<PAGE>

4.    DOMESTIC AND FOREIGN OPERATIONS
Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):

<TABLE>
<CAPTION>
                          ----------------------------------------------------------------------------------------------------
                                                     For the Three Months Ended February 28, 1999
                          ----------------------------------------------------------------------------------------------------

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                         <C>           <C>            <C>           <C>           <C>             <C>           <C>
Net sales:
   Unaffiliated customers  $10,633        $2,619        $1,684          $937          $885        $    -         $16,758        
   Affiliates                1,366            88            16            30             -        (1,500)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    -------------
      Total                 11,999         2,707          1700           967           885        (1,500)         16,758

Income from operations       1,122           464           196           198           (27)            2           1,955
</TABLE>
<TABLE>
<CAPTION>
                          ---------------------------------------------------------------------------------------------------
                                                     For the Three Months Ended February 28, 1998
                          ----------------------------------------------------------------------------------------------------

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                         <C>           <C>            <C>           <C>           <C>             <C>           <C>
Net sales:
   Unaffiliated customers   $5,047        $2,358        $1,443        $1,121          $186        $    -          $10,155
   Affiliates                  901            61             -            45             -         (1007)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    -------------
      Total                  5,948         2,419         1,443         1,166           186         (1007)         10,155

Income from operations         185           259           128           306            27            11             916
</TABLE>
<TABLE>
<CAPTION>
                          ----------------------------------------------------------------------------------------------------
                                                      For the Nine Months Ended February 28, 1999
                          ----------------------------------------------------------------------------------------------------

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                         <C>           <C>            <C>           <C>           <C>             <C>           <C>
Net sales:
   Unaffiliated customers  $23,131        $7,697        $5,083        $3,153        $1,718      $      -         $40,782
   Affiliates                3,413           255            16           123             -        (3,807)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    -------------
      Total                 26,544         7,952         5,099         3,276         1,718        (3,807)         40,782

Income from operations       1,671         1,224           587           821            64           (20)          4,347
</TABLE>
<TABLE>
<CAPTION>
                          ----------------------------------------------------------------------------------------------------
                                                      For the Nine Months Ended February 28, 1998
                          ----------------------------------------------------------------------------------------------------

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                         <C>           <C>            <C>           <C>           <C>             <C>           <C>
Net sales:
   Unaffiliated customers  $14,570        $7,041        $4,244        $3,200          $566       $     -         $29,621
   Affiliates                2,746           208            18           115             -        (3,087)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    -------------
      Total                 17,316         7,249         4,262         3,315           566        (3,087)         29,621

Income from operations         667           784           392           965            79             4           2,891
</TABLE>
<TABLE>
<CAPTION>
                          -----------------------------------------          -----------------------------------------
                                     February 28, 1999                                     May 31, 1998
                          -----------------------------------------          -----------------------------------------
                                           Total                                              Total
                           Long-lived   Identifiable                          Long-lived   Identifiable
                             Assets        Assets      Net Assets               Assets        Assets      Net Assets
                          ------------- ------------- -------------          ------------- ------------- -------------
<S>                            <C>           <C>           <C>                    <C>           <C>            <C>
U.S.                         $49,043       $73,375       $40,296                $19,826       $47,293       $45,060
Germany                        4,040         8,378         4,852                  4,165         8,085         4,282
Italy                          2,400        10,784          (960)                 2,475         9,944        (1,072)
Canada                         7,893         9,403         1,638                  7,974         9,593         1,404
Other                            473         2,927           812                    445         1,513           758
Eliminations                 (15,793)      (19,738)       (8,062)               (15,442)      (18,884)       (7,999)
                          ============= ============= =============          ============= ============= =============
      Consolidated           $48,056       $85,129       $38,576                $19,443       $57,544       $42,433      
                          ============= ============= =============          ============= ============= =============
</TABLE>
<PAGE>



4.    DOMESTIC AND FOREIGN OPERATIONS (CONTINUED)
The Company's U.S. operation made net export sales to unaffiliated  customers of
approximately  $1,726,000  and $880,000 for the three months ended  February 28,
1999 and 1998,  respectively  and  $3,769,000 and $2,620,000 for the nine months
ended February 28, 1999 and 1998,  respectively.  The Company's German operation
made net export sales to unaffiliated  customers of  approximately  $618,000 and
$472,000 for the three months ended February 28, 1999 and 1998, respectively and
$992,000  and  $846,000  for the nine months  ended  February 28, 1999 and 1998,
respectively.  The  Company's  Canadian  operation  made  export  net  sales  to
unaffiliated  customers  of  approximately  $492,000  and $801,000 for the three
months  ended  February  28,  1999 and 1998,  respectively  and  $1,899,000  and
$2,262,000 for the nine months ended  February 28, 1999 and 1998,  respectively.
Product sales to affiliates are valued at market prices.

5.     COMPREHENSIVE INCOME
In June 1997, the FASB issued  Statement of Financial  Accounting  Standards No.
130, Reporting Comprehensive Income ("Statement 130"). Statement 130 establishes
new  standards for the  reporting  and display of  comprehensive  income and its
components  (revenues,  expenses,  gains,  and  losses) in a full set of general
purpose  financial  statements.  These  new  standards  require  that all  items
recognized  as  components  of  comprehensive  income be reported in a financial
statement  that is  displayed  with  the  same  prominence  as  other  financial
statements. Statement 130 is effective for fiscal years beginning after December
15,  1997.  The  Company  adopted  Statement  130 on  June 1,  1998  and has not
presented  a  statement  of  comprehensive  income  because  the  effect  of the
components of comprehensive income is not material to its consolidated financial
statements.  For the three  months  ended  February  28,  1999 and  1998,  total
comprehensive  income was $98,102 and  $78,958,  respectively,  and for the nine
months  ended   February  28,  1999  and  1998,  was  $2,166,226  and  $890,976,
respectively,  which is comprised of net income and other  comprehensive  income
(losses).  Other comprehensive loss for the three months ended February 28, 1999
and 1998 was ($877,995) and  ($386,265),  respectively  and other  comprehensive
loss for the nine months  ended  February 28, 1999 and 1998 was  ($153,950)  and
($678,309),  respectively,  and consisted of income (losses) on foreign currency
translation adjustments. Accumulated other comprehensive loss as of February 28,
1999 was  ($2,546,446).  The balance  consists of net losses on foreign currency
translation  adjustments  and has been  disclosed  in the  shareholders'  equity
section of the condensed consolidated balance sheet.

6.   ACCOUNTS RECEIVABLE, OTHER
In fiscal 1997, Mr. Josef Wilms,  the former  president of the Company's  German
subsidiary, Immucor GmbH, borrowed, prior to his resignation,  $300,000 from the
Company at 6% interest,  secured by his warrants to purchase  143,750  shares of
the  Company's  Common  Stock.  At May 31,  1998 the loan  receivable  including
interest  totaled  $167,000,  and at February  28, 1999 the loan and all accrued
interest was fully paid.

In July 1997,  management  of the Company  discovered  that Mr. Wilms had caused
Immucor GmbH to make unauthorized  loans to him since 1994. The amounts advanced
were documented in the records of Immucor GmbH, including interest rates ranging
from 7.75% to 9.5%, and were  generally paid down by the end of each  accounting
period,  but  were  not  disclosed  to the  Company's  management.  The  largest
aggregate  amounts  outstanding  under the  Immucor  GmbH loans were  $29,600 in
fiscal 1994,  $290,000 in fiscal 1995, $669,000 in fiscal 1996 and $1,311,000 in
fiscal 1997. At May 31, 1998 the amount receivable was approximately  $1,300,000
and at February 28, 1999 the loan receivable balance was approximately $169,000.

Mr. Wilms and his family have granted liens on certain property owned by them to
collateralize  the loans from the Company.  The Company believes it has adequate
collateral to extinguish the remaining debt and, with Mr. Wilm's assistance,  is
arranging for the liquidation of this collateral.

7.    ACQUISITION OF GAMMA BIOLOGICALS, INC.
Pursuant to a definitive  merger  agreement dated  September 21, 1998,  Immucor,
through a newly formed subsidiary ("Gamma  Acquisition  Corporation"),  acquired
94.3% of the issued and outstanding  shares of Gamma  Biologicals,  Inc. ("Gamma
Biologicals").   Immucor   purchased   the  shares   from   Gamma   shareholders
("Shareholders")  for a cash  tender  offer  of  $5.40  per  share  for a  total
transaction  value  of  $24,322,753  ("Purchase  Price"),   subject  to  certain
adjustments.  According to the depository for the offer,  4,361,110  shares were
tendered  pursuant to the offer and Immucor  purchased all shares tendered.  The
Purchase Price was determined  through arm's length  negotiations and $5,000,000
of the  Purchase  Price was paid in cash and the  remaining  $19,322,753  of the
Purchase  Price was funded by a $20,000,000  loan from Wachovia Bank of Georgia,
N.A., a U.S. commercial bank, to Gamma Acquisition Corporation.

<PAGE>

7.    ACQUISITION OF GAMMA BIOLOGICALS, INC. (CONTINUED)
On November 4, 1998,  the Company  entered into an interest rate swap  agreement
with a  notional  amount of  $15,000,000  maturing  on the same date of the loan
which converts the loan's  floating rate to a fixed rate. In connection with the
purchase,  there is an outstanding  patent  litigation claim against the Company
and its wholly-owned subsidiary (Gamma Biologicals) for which the outcome is not
yet  determined.  Management  believes it has a meritorious  defense against the
alleged infringement.

Immucor  effected  the  merger  of  Gamma  Acquisition  Corporation  into  Gamma
Biologicals on October 30, 1998. In the merger, each remaining outstanding share
of Gamma  Biologicals  was converted into the right to receive $5.40 net in cash
and Gamma Biologicals became a majority-owned subsidiary of Immucor.

Located in  Houston,  Texas,  Gamma  Biologicals  manufactures  and sells a wide
variety of in-vitro diagnostic  reagents to blood donation centers,  transfusion
departments of hospitals, medical laboratories and research institutions through
a direct sales force and  distributor  network.  The company  accounted  for the
transaction as a purchase business combination. The results of the operations of
Gamma  Biologicals  since October 27, 1998 are included in the 1998 Consolidated
Statements of Income.  Goodwill,  which  represents the excess of costs over net
assets acquired, will be amortized on a straightline basis over 30 years.

The purchase price allocation subject to certain adjustments is as follows:


Current assets                                                   $8,590,559

Property, plant and equipment, net                                7,535,909
Other assets                                                      2,320,447
Excess of costs over net assets acquired - Goodwill              17,078,722
Less:  Liabilities assumed                                       (8,308,458)
                                                             ----------------

Purchase price                                                  $27,217,179
                                                             ================


The pro forma unaudited results of operations for the nine months ended February
28, 1999 and February 28, 1998, assuming consummation of the purchase as of June
1, 1997,  including  financing from the proceeds of a bank loan and ignoring any
cost-saving initiatives are presented below:

                                Nine Months Ended            Nine Months Ended
                                February 28, 1999            February 28, 1998
                            -----------------------      ----------------------

Net sales                            $48,171,710                 $43,460,758
Net income                             1,241,138                   2,114,252

Net income per common share:
     Basic                                   .16                         .26
     Diluted                                 .16                         .25


8.    SUBSEQUENT EVENTS
On March 15, 1999, the Company  acquired the  distribution  rights to market its
products in France and Belgium through the purchase of its former  distributors,
Immunochim  s.a.r.l.  (France) and Medichim S.A.  (Belgium) for a combination of
cash,  Company  stock  options,  and an  incentive  earn  out.  In  addition,  a
non-compete  agreement  and  intellectual  property  were  purchased and will be
amortized  over  the term of the  agreements  and  will be  classified  as other
assets.

On April 6, 1999,  the Company  announced the signing of a definitive  agreement
for the  purchase  of certain  assets of the BCA blood bank  division of Biopool
International, Inc. The total purchase price of $4.5 million includes $3 million
for net working capital and $1.5 million for the product lines.  The transaction
is expected to close on May 1, 1999.


<PAGE>



                                  IMMUCOR, INC.

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations.

    Any  statements   contained   herein  that  are  not  historical   fact  are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform  Act of  1995,  and  involve  risks  and  uncertainties.  All
forward-looking  statements  included in this document are based on  information
available  to the  Company  on the  date  hereof,  and the  Company  assumes  no
obligation  to update any such  forward-looking  statements.  Further  risks are
detailed in the Company's  filings with the Securities and Exchange  Commission,
including  those set forth in its Annual Report on Form 10-K for the fiscal year
ended May 31, 1998.

Financial Condition and Liquidity:

    During the nine months  ended  February 28, 1999 the Company  increased  its
profitability, maintained positive working capital and had no significant change
in the cash from  operating  activities.  As of February 28, 1999, the Company's
cash position totaled  $1,720,774.  For the nine months ended February 28, 1999,
the Company  generated cash from  operating  activities of $1,134,929 and repaid
$1,299,200 of bank debt primarily in Germany and Canada.

    On  October  27,  1998,  the  Company  acquired  94.3%  of  the  issued  and
outstanding common stock of Gamma  Biologicals,  Inc. for a cash tender offer of
$5.40 per share and certain  transaction costs for a total value of $26,661,918.
Approximately  $5,000,000  of the  purchase  price  was  paid  in  cash  and the
remainder was funded by a $20,000,000  loan from the Company's lead bank, use of
Gamma Biologicals,  Inc.'s cash and assuming other liabilities.  In addition, as
of February 28, 1999,  the Company has made  severance  payments  related to the
acquisition in the amount of $1,957,940.

     In June 1997,  the Company  authorized a program to repurchase up to 10% of
its common stock in the open market. During the nine month period ended February
28,  1999 the Company  repurchased  approximately  822,800  shares of its common
stock for  $7,354,007  under  the  program.  To date  925,600  shares  have been
purchased  under the 1997  program.  On August 26, 1998,  the Board of Directors
authorized  the Company to repurchase up to an additional  800,000 shares of its
common stock. The exercise of  approximately  181,000 stock options and warrants
provided $1,330,996 in cash.

     Management  believes that the Company's  current cash and cash  equivalents
balance,  internally  generated funds, and amounts  available under the lines of
credit should be more than  sufficient to support  operations to support planned
product  introduction  and continued  improvement  and  development  of products
during the next 12 months.  Management  also  believes  additional  credit lines
would be available should the need arise for capital improvements,  acquisitions
or other corporate purposes.

Results of Operations:

Net sales

    Net sales for the three months ended February 28, 1999 totaled  $16,758,000,
an increase of $6,603,000 (65%) over last year's $10,155,000. Current year three
month  results  included  $4,560,000 in net sales from Gamma  Biologicals,  Inc.
acquired  on October 27,  1998 (see  Financial  Condition  and  Liquidity).  The
remaining  increase in sales was generated  equally in the US and Europe and was
primarily  due  to  instrumentation  sales.  The  Company  generated  instrument
revenues of $2,200,000 for the quarter and $3,750,000 for the nine month period.
Sales by the  Company's  European  subsidiaries  increased  30% over last year's
total of which 7% was due to  favorable  rates of foreign  exchange in Europe as
compared to the prior period.  For the nine months ended  February 28, 1999, net
sales were $40,782,000 (including Gamma's $6,354,000) compared to $29,621,000 in
the prior year.


<PAGE>



Gross profit

    As a percent of sales,  gross profit for the three months ended February 28,
1999 totaled  54.7%  versus  52.8% for the same period in 1998.  The increase in
gross profit  margin was  primarily  caused by increased  end customer  sales at
higher  margins.  Also,  the  Company  has begun to  recognize  the  benefit  of
increased higher margin reagent sales associated with instrument placements this
quarter.

Operating expenses

    When compared to the prior year, three and nine month periods ended February
28,  1999  research  and  development  costs  increased  $154,000  and  $272,000
respectively with $295,000  year-to-date  additional  research expense resulting
from the  acquisition of Gamma  Biologicals,  Inc. (see Financial  Condition and
Liquidity).

    Selling  and  marketing  expenses  for the  three  and  nine  month  periods
increased $1,256,000 and $2,020,000  respectively as compared to the same period
last year.  Part of the increase was due to the inclusion of Gamma  Biologicals,
Inc.:  $630,000 for three months and $996,000 for nine months.  The remainder of
the increase is  primarily  due to the effect of higher  payroll  expense due to
additional  personnel  required  for  the  Company's  instrumentation  strategy,
increased  expenses for the launch of the ABS2000,  and expansion of its Spanish
and Italian operations.

     Distribution  expenses  increased  $393,000  for the three month period and
$524,000 for the nine month period of which Gamma Biologicals, Inc. accounts for
$273,000 for the quarter and $374,000 for the nine month  period.  The remaining
increase relates to increased shipping activity.

     General and  administrative  expenses for the three and nine month  periods
increased  $656,000 and $1,035,000,  respectively  with  additional  expenses of
$343,000  for three  months and  $535,000  for nine  months  resulting  from the
purchase of Gamma Biologicals,  Inc. and the remainder due to higher expenses as
we expand operations worldwide.

     Merger-related   expenses  are  one-time  expenses  related  to  the  Gamma
Biologicals Inc. acquisition.


Interest income

    Interest income decreased $170,000 for the quarter and $283,000 for the nine
month  period due to lower cash  balances as compared to last year caused by the
purchase of treasury stock and the purchase of Gamma Biologicals, Inc. which was
partially funded by the use of the Company's cash. (see Financial Conditions and
Liquidity).

Interest expense

    When  compared  to the prior  year  three and nine  month  period,  interest
expense  increased  $361,000 and  $428,000.  This is a result of the purchase of
Gamma Biological,  Inc. which was primarily financed with the proceeds of a bank
loan.

Other income(expense)

    Other income increased  $113,000 for the three month period and $198,000 for
the nine month period due to a gain on sale of certain  assets in Europe  during
the current period  compared to higher currency  transaction  losses incurred in
Europe last year.


<PAGE>



Income taxes

    Income tax expense as a percent of pretax income, decreased during the three
month period ended August 31, 1998 and nine month period ended February 28, 1999
due to lower taxes  provided in Germany and the United States as compared to the
prior period.  This is a result of the Company's  ongoing  implementation of tax
planning strategies.

Year 2000

     The  Company is aware of the issues  that many  companies  will face as the
year 2000  approaches.  In order to become year 2000 compliant,  the Company has
set up a project team to address the issue and has taken the following steps:

    Impact  Assessment-  Instances where electronics are used in the Company and
the associated  potential risks have been identified.  The Company believes that
non-information  technology  systems  and its  products  are  not  significantly
impacted.  However,  internal business information software is affected and will
require program changes in order to become year 2000 compliant.

    Third  Party  Impact  Assessment  - The  Company  has  begun to  verify  the
readiness of its significant suppliers and customers through the distribution of
a  questionnaire.  Although this process is not complete,  based on  information
available,  the  Company  has no reason to believe  that any year 2000  problems
encountered  by customers  and suppliers  will have a significant  effect on the
Company's  operations.  The  Company  estimates  that  this  assessment  will be
completed by May 1999.

    Project  Plan - Based on the impact  assessment,  the need to make  software
program changes to the Company's internal business information software has been
identified.  In Europe,  minor software  program changes to existing systems are
being made at a nominal cost making them year 2000  compliant  before the summer
of 1999. In North America,  since the Company had already planned to implement a
new enterprise wide internal business  information  software system by September
1999, the need to make software  changes to the existing system are for the most
part not  required.  The  Company  has entered  into an  agreement  with a major
software  provider for an enterprise wide business  software system that is year
2000 compliant.  The Company's implementation plan is to install the software by
March 1999,  test and modify by October 1999 and be operating by November  1999.
The  Company  has  already  installed  the  software  and is  currently  setting
milestone  completion  dates  during  the  implementation  period  and  will  be
monitoring progress closely.

     Contingency  Plan  -  The  risk  the  Company  faces  is  a  delay  in  the
implementation of the new internal business information software. The Company is
uncertain what the costs  associated with a delay would be or the related impact
on operations,  liquidity and financial condition.  Because of this, the Company
has in place a contingency plan and will begin to make program  modifications to
the existing internal business software in June 1999. The Company estimates that
all  modifications  and testing can be completed within two to three months at a
cost of  approximately  $20,000 which will be expensed as incurred.  Expenses to
date are nominal.

    The Company  believes that it is diligently  addressing  the year 2000 issue
and expects  that  through its actions  year 2000  problems  are not  reasonably
likely to have a material adverse effect on the Company's operations.  There can
be no assurance that such problems will not arise.

<PAGE>


PART II - OTHER INFORMATION



ITEM 6. Exhibits and Reports on Form 8-K.

         (a) The Company has filed the following exhibits with this report:

             27     Financial data schedule.


         (b) On January 11, 1999,  the Company  filed a Form 8-K/A dated October
         27,  1998,  relating  to Item 2 and  Item 7, the  acquisition  of Gamma
         Biologicals,  Inc. On February 8, 1999, the Company filed Amendment No.
         2 to Form 8-K/A dated October 27, 1998,  relating to Item 2 and Item 7,
         the acquisition of Gamma Biologicals, Inc.


<PAGE>


                                   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                 IMMUCOR, INC.
                                 (Registrant)



Date:  April 14, 1999








/s/  Edward L. Gallup        Edward L. Gallup, President








/s/  Steven C. Ramsey        Steven C. Ramsey, Senior Vice President - Finance
                               (Principal Accounting Officer)